Loading...
Market
Story
Moderna's mRNA Mpox Vaccine Shows Strong Protection in Animal Study, Stock Rises 1.44%
Sep 4, 2024, 03:03 PM
Moderna has reported encouraging results for its mRNA mpox vaccine in a recent animal study. The study, which compared the Moderna vaccine to the Jynneos vaccine in monkeys, found that the mRNA vaccine provided significantly stronger protection. Unvaccinated animals had a maximum of 1,448 lesions, Jynneos-vaccinated animals had a maximum of 607 lesions, while mRNA-immunized animals had a maximum of 54 lesions. These promising results come as mpox outbreaks continue to spread in Africa. A Phase 1/2 human trial for the Moderna mpox vaccine is already underway. Moderna's stock rose by 1.44% following the announcement.
View original story
Similar markets
Successful with no major side effects • 25%
Successful with some side effects • 25%
Unsuccessful • 25%
Inconclusive • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Successful with strong immune response • 25%
Moderate success • 25%
No significant effect • 25%
Trial halted • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
United States • 25%
European Union • 25%
Africa • 25%
Other • 25%
